A wristband sweat sensor to diagnose sugar levels from sweat was developed by the researchers from Stanford University School of Medicine along with the University of California. The device can transmit sugar levels data through smartphone after measuring molecular constituents in the sweat collected by the device. But it is not known when the device will be available in the market. Now the researchers are trying to integrate the developed sensor into a smartwatch. The breakthrough findings were to be published in the journal Proceedings of the National Academy of Sciences.
Lucentis (ranibizumab) drug has got the United States Food and Drug Administration (FDA) approval to treat all forms of diabetic retinopathy following drug comparative study trials of laser surgery. The drug already got approval to treat diabetic macular edema (DME). With this new United States FDA approval, Lucentis can be used to manage diabetic retinopathy in patients with or without diabetic macular edema (DME). This is the first vascular endothelial growth factor (VEGF) inhibitor drug approved by U.S. FDA to treat diabetic retinopathy. Other approvals for this drug are
High glucose or sugar levels over a prolonged period of time damages back of the eye (retina) with the growth of abnormal blood vessels. Laser surgery prevents this abnormal growth of blood vessels over retina and improves the supply of blood rich with oxygen and nutrients.
The left ventricle of the heart is the main pumping chamber of the heart. Left ventricle fails in pumping blood to body organs in the end stage of heart failure patients and they require a heart transplant. Usage of a battery operated machine is being considered in those patients to provide support to heart as there is a shortage of donated hearts. The battery operated machines support patients and keep them alive until a heart to transplant is ready.
The UK doctors performed a breakthrough medical procedure with "Left Ventricular Assist Devices" (LVADs) which reverses even severe heart damage condition into normal heart healthy state in the end stage of heart failure patients. They help patients in recovering from their full heart fitness. In some cases, the patient may not require a heart transplant. A heart transplant surgery costs about £69,000. After implanting LVAD machines in the heart, they help left ventricle of the heart in pumping blood. About 40 percent of the heart damage patients made full recovery with Left Ventricular Assist Devices (LVADs), which costs about £80,000.
Trials of these machines in 58 men with heart failure condition were conducted. Fitness level tests were also conducted on them. On the average, each individual received 395 days of LVAD device support. Trial results show
Co-author of the paper was Dr. Guy A MacGowan, a consultant cardiologist at Newcastle Hospitals NHS Foundation Trust and Honorary Clinical Reader at Newcastle University. The paper was published in the Journal Of American College Of Cardiology.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.